Four Weeks of Near-normalization of Blood Glucose Has No Effect on Postprandial GLP-1 and GIP Secretion, but Augments Pancreatic B-cell Responsiveness to a Meal in Patients with Type 2 Diabetes
Overview
Affiliations
Objective: The aim of the present study was to investigate whether 4 weeks of near-normalization of blood glucose (BG) improves incretin hormone secretion and pancreatic B-cell function during a mixed meal.
Research Design And Methods: Nine patients with Type 2 diabetes in poor glycaemic control [glycated haemoglobin (HbA(1c)) 8.0 +/- 0.4%] were investigated before and after 4 weeks of near-normalization of BG (mean BG 6.4 +/- 0.3 mmol/l) using insulin treatment. HbA(1c) after insulin treatment was 6.6 +/- 0.3%. For comparison, nine healthy control subjects were also studied. Postprandial glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) incremental responses were assessed during a mixed meal test. Fasting and postprandial pancreatic B-cell function was determined from calculations of insulin secretion rates in relation to plasma glucose.
Results: There was no difference in IAUC(totalGLP-1) or in IAUC(totalGIP) between the two experimental days. B-cell sensitivity to glucose (insulinogenic index) did not differ before and after insulin treatment in the fasting state (0.21 +/- 0.17 vs. 0.25 +/- 0.10 pmol kg(-1) min(-1)/mmol l(-1)), but improved significantly during the first 30 min after start of the meal (0.28 +/- 0.07 vs. 0.46 +/- 0.06 pmol kg(-1) min(-1)/mmol l(-1)) and during the following 4 h (0.34 +/- 0.09 vs. 0.56 +/- 0.07 pmol kg(-1) min(-1)/ mmol l(-1)). The B-cell responsiveness to changes in plasma glucose, expressed as the slope of the linear relationship between the insulin secretion rate and the concomitant plasma glucose increased from 0.59 +/- 0.16 to 0.94 +/- 0.13 pmol kg(-1) min(-1)/ mmol l(-1) (P < 0.07).
Conclusions: Four weeks of near-normalization of BG had no effect on postprandial secretion of incretin hormones. Nevertheless, several parameters of meal-induced insulin secretion improved after insulin treatment.
Zhang H, Tang H, Gu Y, Tang Z, Zhao X, Zhou R J Diabetes Investig. 2024; 16(2):236-245.
PMID: 39688420 PMC: 11786176. DOI: 10.1111/jdi.14382.
Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management.
Wibawa I, Mariadi I, Somayana G, Krisnawardani Kumbara C, Sindhughosa D World J Diabetes. 2023; 14(5):549-559.
PMID: 37273247 PMC: 10237000. DOI: 10.4239/wjd.v14.i5.549.
Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity.
Holst J Front Nutr. 2022; 9:964406.
PMID: 35990325 PMC: 9386348. DOI: 10.3389/fnut.2022.964406.
Nyirjesy S, Peleckis A, Eiel J, Gallagher K, Doliba A, Tami A Diabetes. 2022; 71(10):2153-2165.
PMID: 35796669 PMC: 9501647. DOI: 10.2337/db22-0399.
Yoshiji S, Hasebe M, Iwasaki Y, Shibue K, Keidai Y, Seno Y Diabetes Ther. 2022; 13(4):733-746.
PMID: 35285007 PMC: 8991285. DOI: 10.1007/s13300-022-01231-1.